Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Motoki Eguchi, Yosuke Minami, Ayumi Kuzume, et al.
Biomedicines (2020) Vol. 8, Iss. 8, pp. 245-245
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

A review of FLT3 inhibitors in acute myeloid leukemia
Jennifer Zhao, Sonal Agarwal, Hiba Ahmad, et al.
Blood Reviews (2021) Vol. 52, pp. 100905-100905
Open Access | Times Cited: 122
The clinical impact of the molecular landscape of acute myeloid leukemia
Sabine Käyser, Mark J. Levis
Haematologica (2023) Vol. 108, Iss. 2, pp. 308-320
Open Access | Times Cited: 73
Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
Kateryna Fedorov, Abhishek Maiti, Marina Konopleva
Cancers (2023) Vol. 15, Iss. 8, pp. 2312-2312
Open Access | Times Cited: 23
AML treatment: conventional chemotherapy and emerging novel agents
Mark Forsberg, Marina Konopleva
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 5, pp. 430-448
Closed Access | Times Cited: 13
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy
Martina Ruglioni, Stefania Crucitta, Giovanna Irene Luculli, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104424-104424
Open Access | Times Cited: 12
Role of Biomarkers in FLT3 AML
Nitika Nitika, Jiao Wei, Ai‐Min Hui
Cancers (2022) Vol. 14, Iss. 5, pp. 1164-1164
Open Access | Times Cited: 32
Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
Yvyin Zhang, Peihong Wang, Yang Wang, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 13
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia
Alireza Mohebbi, Fahimeh Shahriyary, Vida Farrokhi, et al.
Leukemia Research (2024) Vol. 141, pp. 107505-107505
Closed Access | Times Cited: 5
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
Melisa Tecik, Aysun Adan
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1449-1478
Open Access | Times Cited: 22
FLT3-targeted treatment for acute myeloid leukemia
Yasuyuki Arai, SungGi Chi, Yosuke Minami, et al.
International Journal of Hematology (2022) Vol. 116, Iss. 3, pp. 351-363
Closed Access | Times Cited: 20
The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors
Yang Qiu, Ying Li, Meng Chai, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 11
Application of a macrocyclization strategy in kinase inhibitor development
Kun Xing, Shujun Li, Jing Li, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 1
Open Access
Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML
Helene Sieberer, Michela Luciano, Diana Amend, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation
Kun Shi, Ye Hong, Huajing Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Determination of FLT3 mutations and minimal residual deasease monitoring in FLT3-positive acute myeloid leukemia
Yulia Sidorova, Nataliya Severina, Bella Biderman, et al.
Russian journal of hematology and transfusiology (2025) Vol. 70, Iss. 1, pp. 8-26
Open Access
FLT3: A narrative review
Narender Kumar, Shrinidhi Nathany, Anusha Swaminathan, et al.
Cancer Research Statistics and Treatment (2025) Vol. 8, Iss. 1, pp. 66-74
Open Access
Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner
Tianzhuo Zhang, Danna Wei, Yun Zhan, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Targeting FLT3 for treating diseases: FLT3 inhibitors
Qingfeng Rong, Yu Lu, Wen Zhang, et al.
Drug Discovery Today (2025), pp. 104367-104367
Closed Access
Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT
Lexian Tong, Peipei Wang, Xuemei Li, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 4, pp. 3229-3248
Closed Access | Times Cited: 18
Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
Debora Capelli, Diego Menotti, Alessandro Fiorentini, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4315-4315
Open Access | Times Cited: 18
FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms
Baku Acharya, Debasmita Saha, Daniel W. Armstrong, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 7, pp. 798-816
Open Access | Times Cited: 17
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
Salvatore Perrone, Tiziana Ottone, Nadezda Zhdanovskaya, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 2, pp. 223-38
Open Access | Times Cited: 10
Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations
Zhijie Wang, Jiongheng Cai, Jiwei Ren, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 19, pp. 14664-14701
Closed Access | Times Cited: 23
A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
Peihong Wang, Xinhua Xiao, Yuyin Zhang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Targeted therapy of human leukemia xenografts in immunodeficient zebrafish
Ranganatha R. Somasagara, Xiaoyan Huang, Chunyu Xu, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top